|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barata PC and Rini BI: Treatment of renal
cell carcinoma: Current status and future directions. CA Cancer J
Clin. 67:507–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cavaliere C, D'Aniello C, Pepa CD,
Pisconti S, Berretta M and Facchini G: Current and emerging
treatments for metastatic renal cell carcinoma. Curr Cancer Drug
Targets. 18:468–479. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miao D, Margolis CA, Gao W, Voss MH, Li W,
Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, et al:
Genomic correlates of response to immune checkpoint therapies in
clear cell renal cell carcinoma. Science. 359:801–806. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhai W, Ma J, Zhu R, Xu C, Zhang J, Chen
Y, Chen Z, Gong D, Zheng J, Chen C, et al: MiR-532-5p suppresses
renal cancer cell proliferation by disrupting the ETS1-mediated
positive feedback loop with the KRAS-NAP1L1/P-ERK axis. Br J
Cancer. 119:591–604. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu KG, Gupta S and Goel S: Immunotherapy:
Incorporation in the evolving paradigm of renal cancer management
and future prospects. Oncotarget. 8:17313–17327. 2017.PubMed/NCBI
|
|
8
|
Du Y, Pahernik S, Hadaschik B, Teber D,
Duensing S, Jäger D, Hohenfellner M and Grüllich C: Survival and
prognostic factors of patients with renal cell cancer with bone
metastasis in the era of targeted therapy: A single-institution
analysis. Urol Oncol. 34:433.e1–e8. 2016. View Article : Google Scholar
|
|
9
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ridge CA, Pua BB and Madoff DC:
Epidemiology and staging of renal cell carcinoma. Semin Intervent
Radiol. 31:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vašíčková K, Horak P and Vaňhara P: TUSC3:
Functional duality of a cancer gene. Cell Mol Life Sci. 75:849–857.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fan X, Zhang X, Shen J, Zhao H, Yu X, Chen
Y, Zhuang Z, Deng X, Feng H, Wang Y and Peng L: Decreased TUSC3
promotes pancreatic cancer proliferation, invasion and metastasis.
PLoS One. 11:e01490282016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu YF and Dong M: Expression of TUSC3 and
its prognostic significance in colorectal cancer. Pathol Res Pract.
214:1497–1503. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Birnbaum DJ, Adélaïde J, Mamessier E,
Finetti P, Lagarde A, Monges G, Viret F, Gonçalvès A, Turrini O,
Delpero JR, et al: Genome profiling of pancreatic adenocarcinoma.
Genes Chromosomes Cancer. 50:456–465. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arbieva ZH, Banerjee K, Kim SY, Edassery
SL, Maniatis VS, Horrigan SK and Westbrook CA: High-resolution
physical map and transcript identification of a prostate cancer
deletion interval on 8p22. Genome Res. 10:244–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohorko E, Glockshuber R and Aebi M:
Oligosaccharyltrans-ferase: The central enzyme of N-linked protein
glycosylation. J Inherit Metab Dis. 34:869–878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng Y, Cao J, Yao XY, Wang JX, Zhong MZ,
Gan PP and Li JH: TUSC3 induces autophagy in human non-small cell
lung cancer cells through Wnt/beta-catenin signaling. Oncotarget.
8:52960–52974. 2017.PubMed/NCBI
|
|
18
|
Liu K, Xie F, Gao A, Zhang R, Zhang L,
Xiao Z, Hu Q, Huang W, Huang Q, Lin B, et al: SOX2 regulates
multiple malignant processes of breast cancer development through
the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer. 16:622017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amin MB and Edge SB: American Joint
Committee on Cancer. AJCC cancer staging manual. Eighth.
Switzerland: Springer; 2017, View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirata H, Hinoda Y, Ueno K, Majid S, Saini
S and Dahiya R: Role of secreted frizzled-related protein 3 in
human renal cell carcinoma. Cancer Res. 70:1896–1905. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan X, Liu Y, Hou J and Cao G: Targeted
therapies for renal cell carcinoma in Chinese patients: Focus on
everolimus. Onco Targets Ther. 8:313–321. 2015.PubMed/NCBI
|
|
23
|
Pei X, Li M, Zhan J, Yu Y, Wei X, Guan L,
Aydin H, Elson P, Zhou M, He H and Zhang H: Enhanced IMP3
expression activates NF-κB pathway and promotes renal cell
carcinoma progression. PLoS One. 10:e01243382015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanchez-Gastaldo A, Kempf E, González Del
Alba A and Duran I: Systemic treatment of renal cell cancer: A
comprehensive review. Cancer Treat Rev. 60:77–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miao J, Wang L, Zhu M, Xiao W, Wu H, Di M,
Huang Y, Huang S, Han F, Deng X, et al: Long-term survival and late
toxicities of elderly nasopharyngeal carcinoma (NPC) patients
treated by high-total- and fractionated-dose simultaneous modulated
accelerated radiotherapy with or without chemotherapy. Oral Oncol.
89:40–47. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng R, Lian S, Huang X, Guan G, Li X,
Chi P and Xu B: The survival benefit of intensified full-dose XELOX
chemotherapy concomitant to radiotherapy and then resting-period
consolidation chemotherapy in locally advanced rectal cancer. J
Cancer. 10:730–736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie J, Lin W, Huang L, Xu N, Xu A, Chen B,
Watanabe M, Liu C and Huang P: Bufalin suppresses the proliferation
and metastasis of renal cell carcinoma by inhibiting the
PI3K/Akt/mTOR signaling pathway. Oncol Lett. 16:3867–3873.
2018.PubMed/NCBI
|
|
28
|
Chandrasekar T, Klaassen Z, Goldberg H,
Kulkarni GS, Hamilton RJ and Fleshner NE: Metastatic renal cell
carcinoma: Patterns and predictors of metastases-A contemporary
population-based series. Urol Oncol. 35:661.e7–661.e14. 2017.
View Article : Google Scholar
|
|
29
|
Melkonian SC, Daniel CR, Ye Y, Tannir NM,
Karam JA, Matin SF, Wood CG and Wu X: Gene-environment interaction
of genome-wide association study-identified susceptibility loci and
meat-cooking mutagens in the etiology of renal cell carcinoma.
Cancer. 122:108–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deckers IA, van den Brandt PA, van
Engeland M, van Schooten FJ, Godschalk RW, Keszei AP, Hogervorst JG
and Schouten LJ: Potential role of gene-environment interactions in
ion transport mechanisms in the etiology of renal cell cancer. Sci
Rep. 6:342622016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang MJ, Xing LX, Cui M, Yang X, Shi JG,
Li J, Zhang KJ, Zheng ZJ, Zhang FC, Li JL and Gao XC: Association
of TUSC3 gene polymorphisms with non-syndromic mental retardation
based on nuclear families in the Qinba mountain area of China.
Genet Mol Res. 14:5022–5030. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Molinari F, Foulquier F, Tarpey PS,
Morelle W, Boissel S, Teague J, Edkins S, Futreal PA, Stratton MR,
Turner G, et al: Oligosaccharyltransferase-subunit mutations in
nonsyndromic mental retardation. Am J Hum Genet. 82:1150–1157.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mohorko E, Owen RL, Malojčić G, Brozzo MS,
Aebi M and Glockshuber R: Structural basis of substrate specificity
of human oligosaccharyl transferase subunit N33/Tusc3 and its role
in regulating protein N-glycosylation. Structure. 22:590–601. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vandewynckel YP, Laukens D, Geerts A,
Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F and
Van Vlierberghe H: The paradox of the unfolded protein response in
cancer. Anticancer Res. 33:4683–4694. 2013.PubMed/NCBI
|
|
35
|
Zhou H and Clapham DE: Mammalian MagT1 and
TUSC3 are required for cellular magnesium uptake and vertebrate
embryonic development. Proc Natl Acad Sci USA. 106:15750–15755.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
PLOS ONE: Staff: Correction: Decreased
TUSC3 promotes pancreatic cancer proliferation, invasion and
metastasis. PLoS One. 11:e01517522016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pils D, Horak P, Vanhara P, Anees M, Petz
M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, et al:
Methylation status of TUSC3 is a prognostic factor in ovarian
cancer. Cancer. 119:946–954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo J, Zhu H, Jiang H, Cui Y, Wang M, Ni X
and Ma C: The effects of aberrant expression of LncRNA
DGCR5/miR-873-5p/TUSC3 in lung cancer cell progression. Cancer Med.
2018. View Article : Google Scholar
|
|
39
|
Feng S, Zhai J, Lu D, Lin J, Dong X, Liu
X, Wu H, Roden AC, Brandi G, Tavolari S, et al: TUSC3 accelerates
cancer growth and induces epithelial-mesenchymal transition by
upregulating claudin-1 in non-small-cell lung cancer cells. Exp
Cell Res. 373:44–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Horak P, Tomasich E, Vaňhara P,
Kratochvílová K, Anees M, Marhold M, Lemberger CE, Gerschpacher M,
Horvat R, Sibilia M, et al: TUSC3 loss alters the ER stress
response and accelerates prostate cancer growth in vivo. Sci Rep.
4:37392014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gu Y, Pei X, Ren Y, Cai K, Guo K, Chen J,
Qin W, Lin M, Wang Q, Tang N, et al: Oncogenic function of TUSC3 in
non-small cell lung cancer is associated with Hedgehog signalling
pathway. Biochim Biophys Acta Mol Basis Dis. 1863:1749–1760. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kratochvílová K, Horak P, Ešner M, Souček
K, Pils D, Anees M, Tomasich E, Dráfi F, Jurtíková V, Hampl A, et
al: Tumor suppressor candidate 3 (TUSC3) prevents the
epithelial-to-mesenchymal transition and inhibits tumor growth by
modulating the endoplasmic reticulum stress response in ovarian
cancer cells. Int J Cancer. 137:1330–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Duppel U, Woenckhaus M, Schulz C, Merk J
and Dietmaier W: Quantitative detection of TUSC3 promoter
methylation-a potential biomarker for prognosis in lung cancer.
Oncol Lett. 12:3004–3012. 2017. View Article : Google Scholar
|
|
44
|
Gu Y, Wang Q, Guo K, Qin W, Liao W, Wang
S, Ding Y and Lin J: TUSC3 promotes colorectal cancer progression
and epithelial-mesenchymal transition (EMT) through WNT/β-catenin
and MAPK signalling. J Pathol. 239:60–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bova GS, Carter BS, Bussemakers MJ, Emi M,
Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh
PC, et al: Homozygous deletion and frequent allelic loss of
chromosome 8p22 loci in human prostate cancer. Cancer Res.
53:3869–3873. 1973.
|
|
46
|
Vaňhara P, Horak P, Pils D, Anees M, Petz
M, Gregor W, Zeillinger R and Krainer M: Loss of the oligosaccharyl
transferase subunit TUSC3 promotes proliferation and migration of
ovarian cancer cells. Int J Oncol. 42:1383–1389. 2013. View Article : Google Scholar : PubMed/NCBI
|
